Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Iodinated I-125 Albumin

×

Overview

What is Jeanatope?

Jeanatope 1-125 (Iodinated 1-125 Albumin Injection) is a sterile, nonpyrogenic,

aqueous solution for intravenous use. Each milliliter provides approximately 10

mg protein (normal human serum albumin), 1.6 mg sodium phosphate, 16 mg

sodium biphosphate, not more than 0.4 mg guanidine hydrochloride, sodium

chloride for isotonicity, and 9 mg benzyl alcohol as a preservative. The

stabilizer aceryltryptophanate and sodium caprylate have a concentration of less

than 0.0089M. The pH has been adjusted to 7.2-7.8 with sodium hydroxide or

hydrochloric acid.

Jeanotope I-125 was prepared from the blood that was non-reactive when tested

for hepatitis B surface antigen (HBsAg) and HIV antibody.



What does Jeanatope look like?



What are the available doses of Jeanatope?

Sorry No records found.

What should I talk to my health care provider before I take Jeanatope?

Sorry No records found

How should I use Jeanatope?

Jeanotope I-125 is indicated for use in the determination of total blood and plasma volume.

Radioiodinated serum albumin is administered intravenously.

procedure such as a blood volume determination is to be repeated, the total

dosage administered in any one week should not exceed 7.4 megabecquerels

(200 microcuries).

     To minimise the uptake of radioactive iodine by the thyroid, prior

administration of Lugol's Solution (Strong Iodine Solution USP) may be used.

Ten drops of Lugol's Solution three times a daily, beginning at least 24 hours

before administration of Iodinated Serum Albumin I-125 and continuing for one

or two weeks thereafter, is a suitable dose.

      Complete assay data for each vial are provided on the container.

Note:

properties of the material and not to the radioactivity label, it is important to

make certain that the radioactivity in the dose at the time of administration is

sufficient for the intended use.


What interacts with Jeanatope?

Sorry No Records found


What are the warnings of Jeanatope?

Sorry No Records found


What are the precautions of Jeanatope?

Sorry No Records found


What are the side effects of Jeanatope?

Sorry No records found


What should I look out for while using Jeanatope?

At present there are no known contraindications to the use of this preparation.

Radiopharmaceuticals should not be administered to patients who are pregnant

or to nursing mothers unless the expected benefit to be gained outweighs

the potential hazards.

Since I-125 is excreted in human milk during lactation, formula-feedings

should be substituted for breast-feedings. 

Ideally, examinations using radiopharmaceuticats, especially those elective in

nature, of a woman of childbearing capability should be performed during the 

first few (approximately 10) days following the onset of menses.

A few instances of hyperpyrexia and aseptic (chemical) meningeal irritation

have been reported with the use of this product in cisternography. This material

is not approved for use in cisternography.


What might happen if I take too much Jeanatope?

Sorry No Records found


How should I store and handle Jeanatope?

StorageStore Pantoprazole Sodium Delayed-Release Tablets at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) see USP Controlled Room Temperature.StorageStore Pantoprazole Sodium Delayed-Release Tablets at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) see USP Controlled Room Temperature.Jeanotope (Iodinated I-125 Albumin Injection USP) is available in multiple dosevials containing the following amounts of activity on the date of calibration: 3.7megabequerels /10.0 ml (100 microcuries/10.0 ml), 18.5 megabequerels/0.5 ml(500 microcuries/0.5 ml) and 37.0 megabequerels/1.0 ml (1.0 millicuries/1.0ml). Complete assay data for each vial is provided on the container.      The maximum concentration of Iodinated I-125 Injection does not exceedone millicurie per milliliter at time of calibration.Jeanotope (Iodinated I-125 Albumin Injection USP) is available in multiple dosevials containing the following amounts of activity on the date of calibration: 3.7megabequerels /10.0 ml (100 microcuries/10.0 ml), 18.5 megabequerels/0.5 ml(500 microcuries/0.5 ml) and 37.0 megabequerels/1.0 ml (1.0 millicuries/1.0ml). Complete assay data for each vial is provided on the container.      The maximum concentration of Iodinated I-125 Injection does not exceedone millicurie per milliliter at time of calibration.Jeanotope (Iodinated I-125 Albumin Injection USP) is available in multiple dosevials containing the following amounts of activity on the date of calibration: 3.7megabequerels /10.0 ml (100 microcuries/10.0 ml), 18.5 megabequerels/0.5 ml(500 microcuries/0.5 ml) and 37.0 megabequerels/1.0 ml (1.0 millicuries/1.0ml). Complete assay data for each vial is provided on the container.      The maximum concentration of Iodinated I-125 Injection does not exceedone millicurie per milliliter at time of calibration.Jeanotope (Iodinated I-125 Albumin Injection USP) is available in multiple dosevials containing the following amounts of activity on the date of calibration: 3.7megabequerels /10.0 ml (100 microcuries/10.0 ml), 18.5 megabequerels/0.5 ml(500 microcuries/0.5 ml) and 37.0 megabequerels/1.0 ml (1.0 millicuries/1.0ml). Complete assay data for each vial is provided on the container.      The maximum concentration of Iodinated I-125 Injection does not exceedone millicurie per milliliter at time of calibration.Jeanotope (Iodinated I-125 Albumin Injection USP) is available in multiple dosevials containing the following amounts of activity on the date of calibration: 3.7megabequerels /10.0 ml (100 microcuries/10.0 ml), 18.5 megabequerels/0.5 ml(500 microcuries/0.5 ml) and 37.0 megabequerels/1.0 ml (1.0 millicuries/1.0ml). Complete assay data for each vial is provided on the container.      The maximum concentration of Iodinated I-125 Injection does not exceedone millicurie per milliliter at time of calibration.Jeanotope (Iodinated I-125 Albumin Injection USP) is available in multiple dosevials containing the following amounts of activity on the date of calibration: 3.7megabequerels /10.0 ml (100 microcuries/10.0 ml), 18.5 megabequerels/0.5 ml(500 microcuries/0.5 ml) and 37.0 megabequerels/1.0 ml (1.0 millicuries/1.0ml). Complete assay data for each vial is provided on the container.      The maximum concentration of Iodinated I-125 Injection does not exceedone millicurie per milliliter at time of calibration.Jeanotope (Iodinated I-125 Albumin Injection USP) is available in multiple dosevials containing the following amounts of activity on the date of calibration: 3.7megabequerels /10.0 ml (100 microcuries/10.0 ml), 18.5 megabequerels/0.5 ml(500 microcuries/0.5 ml) and 37.0 megabequerels/1.0 ml (1.0 millicuries/1.0ml). Complete assay data for each vial is provided on the container.      The maximum concentration of Iodinated I-125 Injection does not exceedone millicurie per milliliter at time of calibration.


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Following intravenous injection, radioiodinated serum albumin is uniformly

distributed throughout the intravascular pool within 10 minutes; extravascular

distribution takes place more slowly. Labeled albumin also can be detected in

the lymph and in certain body tissues within 10 minutes after injection, but

maximum distribution of radioactivity throughout the extravascular space does

not occur until two to four days after administration. The time at which

extravascular activity is maximal has been designated as the "equilibrium time."

When this point has been reached, the radioactivity remaining in the

intravascular and extravascular spaces decreases slowly and exponentially in

parallel fashion.

    The administered radioactivity is eliminated almost entirely in the urine, only

about 2 percent of the total dose ultimately appearing in the feces. The biologic

half-life of labeled albumin is dependent upon a number of factors, and

published studies have varied considerably in their reporting of this figure. It

has ranged, in the literature, from below 10 days to over 20 days. One important

factor affecting the biologic half-life is the initial rate of excretion, and this

depends in part on the quality of the labeled albumin. With Jeanatope 1-125 the

biologic half-life in normal individuals has been reported to be approximately 14

days.

Non-Clinical Toxicology
At present there are no known contraindications to the use of this preparation.

Radiopharmaceuticals should not be administered to patients who are pregnant

or to nursing mothers unless the expected benefit to be gained outweighs

the potential hazards.

Since I-125 is excreted in human milk during lactation, formula-feedings

should be substituted for breast-feedings. 

Ideally, examinations using radiopharmaceuticats, especially those elective in

nature, of a woman of childbearing capability should be performed during the 

first few (approximately 10) days following the onset of menses.

A few instances of hyperpyrexia and aseptic (chemical) meningeal irritation

have been reported with the use of this product in cisternography. This material

is not approved for use in cisternography.

In the use of any radioactive material, care should be taken to insure minimum

radiation exposure to the patient and occupational workers consistent with

proper patient management.

Although the immunological properties of serum albumin are believed to be

virtually unaltered by the iodinated process, there is a theoretical possibility that

allergic reactions may occur in patients receiving additional doses a number of 

weeks after an initial dose.

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).